131.87 USD
-0.05 (-0.04%)
131.92 USD
+0.05 (+0.04%)
Taking everything into account, ITCI scores 5 out of 10 in our fundamental rating. ITCI was compared to 192 industry peers in the Pharmaceuticals industry. ITCI has a great financial health rating, but its profitability evaluates not so good. ITCI is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year ITCI has reported negative net income.
ITCI had a negative operating cash flow in the past year.
ITCI had negative earnings in each of the past 5 years.
In the past 5 years ITCI always reported negative operating cash flow.
1.2 Ratios
With a decent Return On Assets value of -5.46%, ITCI is doing good in the industry, outperforming 73.37% of the companies in the same industry.
With a decent Return On Equity value of -6.50%, ITCI is doing good in the industry, outperforming 78.39% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.46% | ||
| ROE | -6.5% | ||
| ROIC | N/A |
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ITCI's Gross Margin of 91.63% is amongst the best of the industry. ITCI outperforms 94.97% of its industry peers.
ITCI's Gross Margin has been stable in the last couple of years.
ITCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
2. Health
2.1 Basic Checks
ITCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
ITCI has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ITCI has more shares outstanding
There is no outstanding debt for ITCI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
ITCI has an Altman-Z score of 38.03. This indicates that ITCI is financially healthy and has little risk of bankruptcy at the moment.
ITCI has a better Altman-Z score (38.03) than 97.49% of its industry peers.
There is no outstanding debt for ITCI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 38.03 |
ROIC/WACCN/A
WACC9.49%
2.3 Liquidity
ITCI has a Current Ratio of 6.36. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
ITCI's Current ratio of 6.36 is fine compared to the rest of the industry. ITCI outperforms 76.38% of its industry peers.
ITCI has a Quick Ratio of 6.23. This indicates that ITCI is financially healthy and has no problem in meeting its short term obligations.
ITCI has a better Quick ratio (6.23) than 76.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.36 | ||
| Quick Ratio | 6.23 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 50.00% over the past year.
Looking at the last year, ITCI shows a very strong growth in Revenue. The Revenue has grown by 46.61%.
ITCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 484.27% yearly.
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
3.2 Future
ITCI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 87.04% yearly.
The Revenue is expected to grow by 37.51% on average over the next years. This is a very strong growth
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
ITCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
ITCI is valuated quite expensively with a Price/Forward Earnings ratio of 660.59.
ITCI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. ITCI is cheaper than 73.37% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, ITCI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 660.59 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as ITCI's earnings are expected to grow with 140.69% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y174.17%
EPS Next 3Y140.69%
5. Dividend
5.1 Amount
No dividends for ITCI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
131.87
-0.05 (-0.04%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners94.75%
Inst Owner Change-26.2%
Ins Owners0.23%
Ins Owner Change0%
Market Cap14.05B
Revenue(TTM)680.85M
Net Income(TTM)-74.68M
Analysts72.22
Price Target133.21 (1.02%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-32.8%
Min EPS beat(2)-40.63%
Max EPS beat(2)-24.97%
EPS beat(4)2
Avg EPS beat(4)0.62%
Min EPS beat(4)-40.63%
Max EPS beat(4)50.59%
EPS beat(8)6
Avg EPS beat(8)17.95%
EPS beat(12)9
Avg EPS beat(12)16.57%
EPS beat(16)10
Avg EPS beat(16)13.07%
Revenue beat(2)1
Avg Revenue beat(2)0.38%
Min Revenue beat(2)-0.24%
Max Revenue beat(2)1%
Revenue beat(4)3
Avg Revenue beat(4)0.36%
Min Revenue beat(4)-0.24%
Max Revenue beat(4)1%
Revenue beat(8)6
Avg Revenue beat(8)0.51%
Revenue beat(12)9
Avg Revenue beat(12)1.93%
Revenue beat(16)11
Avg Revenue beat(16)1.25%
PT rev (1m)-0.1%
PT rev (3m)26.18%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.86%
EPS NY rev (1m)-30.48%
EPS NY rev (3m)-47.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)4.15%
Revenue NY rev (1m)0.91%
Revenue NY rev (3m)1.41%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 660.59 | ||
| P/S | 20.63 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 12.23 | ||
| P/tB | 12.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.73
EYN/A
EPS(NY)0.2
Fwd EY0.15%
FCF(TTM)-0.69
FCFYN/A
OCF(TTM)-0.69
OCFYN/A
SpS6.39
BVpS10.78
TBVpS10.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -5.46% | ||
| ROE | -6.5% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 91.63% | ||
| FCFM | N/A |
ROA(3y)-19.53%
ROA(5y)-29.65%
ROE(3y)-23.06%
ROE(5y)-34.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.43%
GM growth 5YN/A
F-Score4
Asset Turnover0.5
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 63.39% | ||
| Cap/Sales | 0.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.36 | ||
| Quick Ratio | 6.23 | ||
| Altman-Z | 38.03 |
F-Score4
WACC9.49%
ROIC/WACCN/A
Cap/Depr(3y)77.5%
Cap/Depr(5y)69.14%
Cap/Sales(3y)0.14%
Cap/Sales(5y)0.4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%46.67%
EPS Next Y127.35%
EPS Next 2Y174.17%
EPS Next 3Y140.69%
EPS Next 5Y87.04%
Revenue 1Y (TTM)46.61%
Revenue growth 3Y101.03%
Revenue growth 5Y484.27%
Sales Q2Q%50.81%
Revenue Next Year40.33%
Revenue Next 2Y50.81%
Revenue Next 3Y47.62%
Revenue Next 5Y37.51%
EBIT growth 1Y26.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year126.61%
EBIT Next 3Y133.69%
EBIT Next 5Y90.06%
FCF growth 1Y40.95%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y41.08%
OCF growth 3YN/A
OCF growth 5YN/A
INTRA-CELLULAR THERAPIES INC / ITCI FAQ
Can you provide the ChartMill fundamental rating for INTRA-CELLULAR THERAPIES INC?
ChartMill assigns a fundamental rating of 5 / 10 to ITCI.
Can you provide the valuation status for INTRA-CELLULAR THERAPIES INC?
ChartMill assigns a valuation rating of 1 / 10 to INTRA-CELLULAR THERAPIES INC (ITCI). This can be considered as Overvalued.
Can you provide the profitability details for INTRA-CELLULAR THERAPIES INC?
INTRA-CELLULAR THERAPIES INC (ITCI) has a profitability rating of 2 / 10.
How financially healthy is INTRA-CELLULAR THERAPIES INC?
The financial health rating of INTRA-CELLULAR THERAPIES INC (ITCI) is 8 / 10.